Articles

Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That

If drug developers design trials to measure how well their drug addresses the issues most important to the target patient community, we could expect to end up with better drugs. Integrating patient-reported…

Articles

Molecular tumour boards: translating data into tailored therapeutics

Developments in molecular diagnostics are allowing us to capture an extraordinarily detailed picture of the genomic and other molecular changes that characterise a given tumour specimen. But making best use of the…